Compare HGLB & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HGLB | TNXP |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.7M | 201.0M |
| IPO Year | N/A | N/A |
| Metric | HGLB | TNXP |
|---|---|---|
| Price | $9.16 | $16.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $70.00 |
| AVG Volume (30 Days) | 91.8K | ★ 509.0K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 13.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,299,000.00 |
| Revenue This Year | N/A | $2.96 |
| Revenue Next Year | N/A | $750.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.42 | $6.76 |
| 52 Week High | $9.45 | $69.97 |
| Indicator | HGLB | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 37.99 |
| Support Level | $8.96 | $17.71 |
| Resistance Level | $9.39 | $19.35 |
| Average True Range (ATR) | 0.24 | 1.07 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 24.88 | 5.40 |
Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.